Open Access Highly Accessed Study protocol

The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study

Justin A Ezekowitz14*, Harald Becher14, Israel Belenkie23, Alexander M Clark16, Henry J Duff23, Matthias G Friedrich378, Mark J Haykowsky19, Jonathan G Howlett23, Zamaneh Kassiri110, Padma Kaul4, Daniel H Kim14, Merril L Knudtson23, Peter E Light11112, Gary D Lopaschuk15, Finlay A McAlister14, Michelle L Noga113, Gavin Y Oudit14, D Ian Paterson14, Hude Quan23, Richard Schulz1125, Richard B Thompson114, Sarah G Weeks23, Todd J Anderson23 and Jason RB Dyck15

Author Affiliations

1 Mazankowski Alberta Heart Institute, 2C2 WMC, 8440-112 Street, Edmonton, AB, Canada

2 Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada

3 Department of Cardiac Sciences, University of Calgary, Calgary, AB, Canada

4 Department of Medicine, University of Alberta, Edmonton, AB, Canada

5 Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

6 Faculty of Nursing, University of Alberta, Edmonton, AB, Canada

7 Department of Radiology, University of Calgary, Calgary, AB, Canada

8 Departments of Medicine and Radiology, Montreal Heart Institute, Université de Montréal, Montréal, QC, Canada

9 Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada

10 Department of Physiology, University of Alberta, Edmonton, AB, Canada

11 Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada

12 Department of Pharmacology, University of Alberta, Edmonton, AB, Canada

13 Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada

14 Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada

For all author emails, please log on.

BMC Cardiovascular Disorders 2014, 14:91  doi:10.1186/1471-2261-14-91

Published: 25 July 2014

Abstract

Background

Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs annually and the global burden is expected to double in the next 1–2 decades. The current one-year mortality rate after diagnosis of heart failure remains high at >25%. Consequently, new therapeutic strategies need to be developed for this debilitating condition.

Methods/Design

The objective of the Alberta HEART program (http://albertaheartresearch.ca webcite) is to develop novel diagnostic, therapeutic and prognostic approaches to patients with heart failure with preserved ejection fraction. We hypothesize that novel imaging techniques and biomarkers will aid in describing heart failure with preserved ejection fraction. Furthermore, the development of new diagnostic criteria will allow us to: 1) better define risk factors associated with heart failure with preserved ejection fraction; 2) elucidate clinical, cellular and molecular mechanisms involved with the development and progression of heart failure with preserved ejection fraction; 3) design and test new therapeutic strategies for patients with heart failure with preserved ejection fraction. Additionally, Alberta HEART provides training and education for enhancing translational medicine, knowledge translation and clinical practice in heart failure. This is a prospective observational cohort study of patients with, or at risk for, heart failure. Patients will have sequential testing including quality of life and clinical outcomes over 12 months. After that time, study participants will be passively followed via linkage to external administrative databases. Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant. Patients will be followed for a total of 5 years.

Discussion

Alberta HEART has the primary objective to define new diagnostic criteria for patients with heart failure with preserved ejection fraction. New criteria will allow for targeted therapies, diagnostic tests and further understanding of the patients, both at-risk for and with heart failure.

Trial registration

ClinicalTrials.gov NCT02052804.

Keywords:
Heart failure; Preserved ejection fraction; Heart failure risk factors; Heart failure diagnosis